Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad) Buy HIMS Stock  Free HIMS Stock Alerts

Hims & Hers Health (HIMS) Financials

Hims & Hers Health logo
$33.06 -1.98 (-5.65%)
As of 03:59 PM Eastern
Compare
Annual Income Statements for Hims & Hers Health

Annual Income Statements for Hims & Hers Health

This table shows Hims & Hers Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -72 -18 -108 -66 -24 126
Consolidated Net Income / (Loss)		 -72 -18 -108 -66 -24 126
Net Income / (Loss) Continuing Operations		 -72 -18 -108 -66 -24 126
Total Pre-Tax Income 		-72 -18 -111 -66 -22 72
Total Operating Income		 -74 -15 -115 -69 -29 62
Total Gross Profit		 45 109 204 409 715 1,173
Total Revenue		 83 149 272 527 872 1,477
Operating Revenue		 83 149 272 527 872 1,477
Total Cost of Revenue		 38 39 67 118 157 303
Operating Cost of Revenue		 38 39 67 118 157 303
Total Operating Expenses		 119 125 320 477 744 1,111
Selling, General & Admin Expense		 56 26 114 98 130 168
Marketing Expense		 63 59 136 273 446 679
Research & Development Expense		 - 11 22 29 48 79
Other Operating Expenses / (Income)		 - 28 48 77 120 186
Total Other Income / (Expense), net		 2.44 -2.84 4.25 2.99 7.88 9.81
Other Income / (Expense), net		 2.81 -2.84 4.25 2.99 7.88 9.81
Income Tax Expense		 0.09 0.13 -3.14 -0.03 1.98 -54
Basic Earnings per Share		 ($2.07) ($0.51) ($0.58) ($0.32) ($0.11) $0.58
Weighted Average Basic Shares Outstanding		 34.76M 35.35M 186.78M 204.52M 209.34M 215.94M
Diluted Earnings per Share		 ($2.07) ($0.51) ($0.58) ($0.32) ($0.11) $0.53
Weighted Average Diluted Shares Outstanding		 34.76M 35.35M 186.78M 204.52M 209.34M 236.81M
Weighted Average Basic & Diluted Shares Outstanding		 - 5.03M 205.07M 208.46M 214.25M 222.17M

Quarterly Income Statements for Hims & Hers Health

This table shows Hims & Hers Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -19 -11 -10 -7.16 -7.57 1.25 11 13 76 26
Consolidated Net Income / (Loss)		 -19 -11 -10 -7.16 -7.57 1.25 11 13 76 26
Net Income / (Loss) Continuing Operations		 -19 -11 -10 -7.16 -7.57 1.25 11 13 76 26
Total Pre-Tax Income 		-19 -11 -9.68 -7.17 -6.92 2.20 12 13 24 22
Total Operating Income		 -20 -12 -11 -9.24 -8.55 -0.40 9.90 11 22 19
Total Gross Profit		 114 132 153 170 187 204 229 257 318 370
Total Revenue		 145 167 191 208 227 247 278 316 402 481
Operating Revenue		 145 167 191 208 227 247 278 316 402 481
Total Cost of Revenue		 30 35 37 38 39 43 49 59 84 112
Operating Cost of Revenue		 30 35 37 38 39 43 49 59 84 112
Total Operating Expenses		 134 144 165 179 196 204 219 246 296 351
Selling, General & Admin Expense		 26 28 31 31 36 32 35 41 45 48
Marketing Expense		 78 86 97 107 116 126 131 145 182 221
Research & Development Expense		 7.98 8.31 11 12 12 13 15 19 21 24
Other Operating Expenses / (Income)		 22 23 26 29 32 33 39 41 48 58
Total Other Income / (Expense), net		 1.13 0.58 1.58 2.07 1.64 2.60 2.50 2.39 1.22 3.70
Other Income / (Expense), net		 1.13 0.58 1.58 2.07 1.64 2.60 2.50 2.39 1.22 3.70
Income Tax Expense		 -0.02 -0.12 0.39 -0.01 0.65 0.95 1.28 0.13 -52 -3.73
Basic Earnings per Share		 ($0.09) ($0.05) ($0.05) ($0.03) ($0.04) $0.01 $0.05 $0.06 $0.35 $0.12
Weighted Average Basic Shares Outstanding		 205.23M 204.52M 207.14M 208.42M 210.13M 209.34M 213.45M 214.62M 216.62M 215.94M
Diluted Earnings per Share		 ($0.09) ($0.05) ($0.05) ($0.03) ($0.04) $0.01 $0.05 $0.06 $0.32 $0.10
Weighted Average Diluted Shares Outstanding		 205.23M 204.52M 207.14M 208.42M 210.13M 209.34M 229.36M 234.79M 235.07M 236.81M
Weighted Average Basic & Diluted Shares Outstanding		 207.74M 208.46M 209.32M 211.02M 211.99M 214.25M 214.79M 217.08M 218.48M 222.17M

Annual Cash Flow Statements for Hims & Hers Health

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -19 5.55 44 -25 50 124
Net Cash From Operating Activities		 -75 -2.48 -34 -27 73 251
Net Cash From Continuing Operating Activities		 -75 -2.48 -34 -27 73 251
Net Income / (Loss) Continuing Operations		 -72 -18 -108 -66 -24 126
Consolidated Net Income / (Loss)		 -72 -18 -108 -66 -24 126
Depreciation Expense		 0.26 1.06 4.08 7.47 9.52 17
Amortization Expense		 -0.13 0.65 2.31 0.15 -5.69 -4.36
Non-Cash Adjustments To Reconcile Net Income		 6.92 9.75 67 36 72 93
Changes in Operating Assets and Liabilities, net		 -9.85 4.19 0.07 -4.61 21 20
Net Cash From Investing Activities		 -39 -40 -156 35 -12 -19
Net Cash From Continuing Investing Activities		 -39 -40 -156 35 -12 -19
Purchase of Property, Plant & Equipment		 -1.79 -4.23 -5.01 -7.25 -26 -53
Acquisitions		 0.00 0.00 -46 -0.46 0.00 -15
Purchase of Investments		 -42 -95 -267 -188 -157 -161
Sale and/or Maturity of Investments		 4.50 60 162 230 172 210
Net Cash From Financing Activities		 95 48 235 -33 -11 -108
Net Cash From Continuing Financing Activities		 95 48 235 -33 -11 -108
Repurchase of Common Equity		 0.00 -3.36 -35 0.00 -2.00 -83
Issuance of Common Equity		 0.00 0.00 75 1.18 2.30 3.90
Other Financing Activities, net		 0.04 0.68 194 -34 -12 -29
Effect of Exchange Rate Changes		 -0.01 -0.01 -0.07 -0.05 -0.01 -0.27
Cash Income Taxes Paid		 0.14 0.22 0.34 0.64 1.11 7.92

Quarterly Cash Flow Statements for Hims & Hers Health

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 2.93 -11 1.97 17 -7.42 39 8.57 24 36 55
Net Cash From Operating Activities		 5.99 -6.72 9.48 17 25 22 26 54 85 86
Net Cash From Continuing Operating Activities		 5.99 -6.72 9.48 17 25 22 26 54 85 86
Net Income / (Loss) Continuing Operations		 -19 -11 -10 -7.16 -7.57 1.25 11 13 76 26
Consolidated Net Income / (Loss)		 -19 -11 -10 -7.16 -7.57 1.25 11 13 76 26
Depreciation Expense		 1.90 2.01 2.12 2.38 2.36 2.66 3.00 3.64 4.38 6.06
Amortization Expense		 0.12 -0.84 -1.04 -1.48 -1.52 -1.65 -1.08 -1.20 -1.16 -0.92
Non-Cash Adjustments To Reconcile Net Income		 12 11 16 18 20 19 20 22 26 25
Changes in Operating Assets and Liabilities, net		 11 -8.42 2.45 5.17 12 0.88 -7.30 16 -19 30
Net Cash From Investing Activities		 -2.58 6.00 -4.11 2.37 -31 21 13 -4.47 -10 -17
Net Cash From Continuing Investing Activities		 -2.58 6.00 -4.11 2.37 -31 21 13 -4.47 -10 -17
Purchase of Property, Plant & Equipment		 -1.96 -2.61 -2.51 -6.86 -5.92 -11 -14 -6.03 -5.88 -27
Purchase of Investments		 -48 -51 -41 -25 -71 -21 -71 -27 -53 -9.97
Sale and/or Maturity of Investments		 47 60 39 34 46 53 98 28 64 20
Net Cash From Financing Activities		 -0.49 -10 -3.41 -2.54 -1.56 -3.96 -30 -25 -39 -14
Net Cash From Continuing Financing Activities		 -0.49 -10 -3.41 -2.54 -1.56 -3.96 -30 -25 -39 -14
Repurchase of Common Equity		 - - 0.00 - - -2.00 -28 -20 -30 -5.01
Issuance of Common Equity		 - 0.63 - - - 1.40 - - - 2.28
Other Financing Activities, net		 -0.49 -11 -3.41 -3.44 -1.56 -3.36 -2.24 -6.76 -8.78 -11
Effect of Exchange Rate Changes		 0.02 -0.02 0.02 0.01 0.01 -0.05 0.00 -0.00 0.19 -0.46
Cash Income Taxes Paid		 0.06 0.05 0.29 0.34 0.02 0.46 0.13 3.34 0.40 4.04

Annual Balance Sheets for Hims & Hers Health

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 205 119 421 366 441 708
Total Current Assets		 1.66 113 270 217 265 396
Cash & Equivalents		 1.51 27 72 47 97 221
Short-Term Investments		 - 73 175 133 124 80
Inventories, net		 - 3.54 14 22 22 64
Prepaid Expenses		 0.15 5.40 9.07 15 22 31
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 203 5.61 151 150 176 312
Goodwill		 - 0.00 111 111 111 113
Intangible Assets		 - 0.06 26 22 19 43
Noncurrent Deferred & Refundable Income Taxes		 - - - - 0.00 62
Other Noncurrent Operating Assets		 203 5.55 14 17 47 94
Total Liabilities & Shareholders' Equity		 205 119 421 366 441 708
Total Liabilities		 8.17 16 86 55 97 231
Total Current Liabilities		 0.98 15 79 48 88 221
Short-Term Debt		 - 0.00 43 0.00 7.41 0.00
Accounts Payable		 0.45 8.07 20 32 43 91
Accrued Expenses		 0.53 4.98 12 12 29 53
Current Deferred Revenue		 - 1.27 3.19 1.47 7.73 75
Other Current Liabilities		 - 0.91 1.37 1.66 1.28 1.89
Total Noncurrent Liabilities		 7.19 0.38 6.75 6.66 8.69 9.46
Other Noncurrent Operating Liabilities		 7.19 0.38 6.75 6.66 8.69 9.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.00 -147 335 312 344 477
Total Preferred & Common Equity		 5.00 -147 335 312 344 477
Total Common Equity		 5.00 -147 335 312 344 477
Common Stock		 3.85 24 614 657 712 719
Retained Earnings		 1.15 -171 -279 -345 -368 -242
Accumulated Other Comprehensive Income / (Loss)		 - -0.01 -0.14 -0.28 -0.12 -0.32

Quarterly Balance Sheets for Hims & Hers Health

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 383 376 390 414 448 481 602
Total Current Assets		 233 226 235 250 262 291 326
Cash & Equivalents		 58 49 65 58 105 129 166
Short-Term Investments		 140 136 128 155 98 98 89
Inventories, net		 22 21 21 22 30 41 49
Prepaid Expenses		 13 20 20 16 28 23 23
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 149 151 155 164 186 190 276
Goodwill		 111 111 111 111 111 111 113
Intangible Assets		 22 21 20 19 18 17 45
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - 54
Other Noncurrent Operating Assets		 16 19 24 33 58 62 64
Total Liabilities & Shareholders' Equity		 383 376 390 414 448 481 602
Total Liabilities		 72 64 70 85 104 119 162
Total Current Liabilities		 67 56 67 83 93 109 153
Short-Term Debt		 13 - 4.78 6.86 7.41 0.00 0.00
Accounts Payable		 33 38 38 42 44 57 75
Accrued Expenses		 17 14 20 27 27 29 43
Current Deferred Revenue		 2.12 2.87 2.06 4.39 14 21 32
Other Current Liabilities		 1.61 1.69 1.84 1.93 1.54 1.63 1.79
Total Noncurrent Liabilities		 5.06 7.28 3.27 2.76 10 9.86 9.57
Other Noncurrent Operating Liabilities		 5.06 7.28 3.27 2.76 10 9.86 9.57
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 311 313 320 329 344 362 440
Total Preferred & Common Equity		 311 313 320 329 344 362 440
Total Common Equity		 311 313 320 329 344 362 440
Common Stock		 645 668 682 698 702 706 708
Retained Earnings		 -334 -355 -362 -369 -357 -344 -268
Accumulated Other Comprehensive Income / (Loss)		 -0.46 -0.11 -0.26 -0.13 -0.16 -0.17 0.23

Annual Metrics and Ratios for Hims & Hers Health

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 80.18% 82.77% 93.81% 65.49% 69.33%
EBITDA Growth		 0.00% 77.22% -541.22% 44.36% 69.46% 575.96%
EBIT Growth		 0.00% 74.88% -515.97% 40.69% 67.17% 432.44%
NOPAT Growth		 0.00% 79.65% -659.65% 40.29% 57.13% 627.72%
Net Income Growth		 0.00% 74.86% -494.34% 38.99% 64.15% 635.28%
EPS Growth		 0.00% 75.36% -13.73% 44.83% 65.63% 581.82%
Operating Cash Flow Growth		 0.00% 96.69% -1,288.14% 22.90% 376.97% 241.69%
Free Cash Flow Firm Growth		 0.00% 0.00% -214.44% 75.93% 62.10% 431.18%
Invested Capital Growth		 0.00% -98.52% 4,420.10% 1.49% -1.25% 35.26%
Revenue Q/Q Growth		 0.00% 0.00% 18.91% 18.56% 10.02% 18.88%
EBITDA Q/Q Growth		 0.00% 0.00% -31.04% 24.96% 42.53% 40.25%
EBIT Q/Q Growth		 0.00% 0.00% -30.71% 23.53% 38.13% 38.93%
NOPAT Q/Q Growth		 0.00% 0.00% -17.27% 12.66% 27.56% 29.26%
Net Income Q/Q Growth		 0.00% 0.00% -31.73% 23.57% 34.04% 24.47%
EPS Q/Q Growth		 0.00% 0.00% 6.45% 15.79% 35.29% 20.45%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -8.98% -15.77% 64.09% 34.50%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 8.47% 26.68% 197.32%
Invested Capital Q/Q Growth		 0.00% 0.00% 3.37% 5.25% 6.13% -5.12%
Profitability Metrics		 - - - - - -
Gross Margin		 54.03% 73.58% 75.22% 77.57% 81.99% 79.45%
EBITDA Margin		 -86.58% -10.95% -38.40% -11.02% -2.03% 5.72%
Operating Margin		 -90.14% -10.18% -42.31% -13.04% -3.38% 4.19%
EBIT Margin		 -86.73% -12.09% -40.75% -12.47% -2.47% 4.86%
Profit (Net Income) Margin		 -87.29% -12.18% -39.60% -12.46% -2.70% 8.54%
Tax Burden Percent		 100.13% 100.71% 97.17% 99.95% 109.16% 175.76%
Interest Burden Percent		 100.52% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% -75.76%
Return on Invested Capital (ROIC)		 -26.70% -10.71% -121.04% -36.67% -15.70% 70.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 1,295.79% 4.06% -103.23% -27.51% -14.21% 64.19%
Return on Net Nonoperating Assets (RNNOA)		 -9.96% -1.38% 71.85% 16.34% 8.52% -40.18%
Return on Equity (ROE)		 -36.66% -12.09% -49.19% -20.32% -7.18% 30.71%
Cash Return on Invested Capital (CROIC)		 0.00% 183.47% -312.39% -38.14% -14.44% 40.92%
Operating Return on Assets (OROA)		 -34.97% -11.12% -41.09% -16.70% -5.34% 12.49%
Return on Assets (ROA)		 -35.19% -11.20% -39.93% -16.69% -5.83% 21.94%
Return on Common Equity (ROCE)		 -0.93% 5.72% -21.10% -20.32% -7.18% 30.71%
Return on Equity Simple (ROE_SIMPLE)		 -1,441.28% 12.33% -32.17% -21.07% -6.84% 26.44%
Net Operating Profit after Tax (NOPAT)		 -52 -11 -81 -48 -21 109
NOPAT Margin		 -63.09% -7.13% -29.62% -9.13% -2.36% 7.37%
Net Nonoperating Expense Percent (NNEP)		 -1,322.50% -14.77% -17.81% -9.16% -1.49% 6.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -15.43% -5.87% 22.82%
Cost of Revenue to Revenue		 45.97% 26.42% 24.78% 22.43% 18.01% 20.55%
SG&A Expenses to Revenue		 67.67% 17.50% 41.81% 18.64% 14.89% 11.36%
R&D to Revenue		 0.00% 7.55% 8.23% 5.55% 5.53% 5.34%
Operating Expenses to Revenue		 144.16% 83.76% 117.53% 90.61% 85.37% 75.26%
Earnings before Interest and Taxes (EBIT)		 -72 -18 -111 -66 -22 72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -71 -16 -104 -58 -18 84
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 49.81 0.00 3.99 4.27 5.48 11.08
Price to Tangible Book Value (P/TBV)		 49.81 0.00 6.75 7.44 8.79 16.48
Price to Revenue (P/Rev)		 3.02 2.47 4.91 2.53 2.16 3.58
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 41.91
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 2.39%
Enterprise Value to Invested Capital (EV/IC)		 2.25 179.53 8.69 8.72 12.83 28.24
Enterprise Value to Revenue (EV/Rev)		 5.32 3.48 4.16 2.19 1.92 3.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 59.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 69.48
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 45.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 22.77 19.84
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 2.85 0.00 0.00 0.00 79.35
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.13 0.00 0.02 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.01 -0.34 -0.70 -0.59 -0.60 -0.63
Leverage Ratio		 1.04 1.08 1.23 1.22 1.23 1.40
Compound Leverage Factor		 1.05 1.08 1.23 1.22 1.23 1.40
Debt to Total Capital		 0.00% 0.00% 11.35% 0.00% 2.11% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 11.35% 0.00% 2.11% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 97.46% 242.47% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 2.54% -142.47% 88.65% 100.00% 97.89% 100.00%
Debt to EBITDA		 0.00 0.00 -0.41 0.00 -0.42 0.00
Net Debt to EBITDA		 0.00 0.00 1.96 0.00 12.04 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.53 0.00 -0.36 0.00
Net Debt to NOPAT		 0.00 0.00 2.54 0.00 10.36 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 17.54 13.84 8.71 14.71 12.78 15.97
Noncontrolling Interest Sharing Ratio		 97.46% 147.34% 57.11% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 1.69 7.43 3.41 4.52 3.00 1.79
Quick Ratio		 1.54 6.58 3.12 3.75 2.50 1.36
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 182 -208 -50 -19 63
Operating Cash Flow to CapEx		 -4,189.54% -58.56% -687.28% -366.10% 277.38% 475.99%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -202.89 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -207.73 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.40 0.92 1.01 1.34 2.16 2.57
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 7.88 6.73 7.13 6.98
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 85.10 9.24 4.86 4.55 4.16 4.52
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 46.32 54.23 51.16 52.27
Days Payable Outstanding (DPO)		 4.29 39.52 75.04 80.30 87.66 80.76
Cash Conversion Cycle (CCC)		 -4.29 -39.52 -28.72 -26.07 -36.50 -28.49
Capital & Investment Metrics		 - - - - - -
Invested Capital		 195 2.88 130 132 130 176
Invested Capital Turnover		 0.42 1.50 4.09 4.02 6.64 9.62
Increase / (Decrease) in Invested Capital		 0.00 -192 127 1.94 -1.66 46
Enterprise Value (EV)		 439 517 1,131 1,152 1,673 4,983
Market Capitalization		 249 367 1,336 1,332 1,887 5,283
Book Value per Share		 $0.20 ($5.84) $1.64 $1.50 $1.62 $2.18
Tangible Book Value per Share		 $0.20 ($5.84) $0.97 $0.86 $1.01 $1.47
Total Capital		 197 103 377 312 351 477
Total Debt		 0.00 0.00 43 0.00 7.41 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.51 -100 -204 -180 -214 -300
Capital Expenditures (CapEx)		 1.79 4.23 5.01 7.25 26 53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.83 -2.35 -14 -11 -37 -126
Debt-free Net Working Capital (DFNWC)		 0.68 98 234 169 184 174
Net Working Capital (NWC)		 0.68 98 191 169 177 174
Net Nonoperating Expense (NNE)		 20 7.51 27 18 2.93 -17
Net Nonoperating Obligations (NNO)		 -1.51 -100 -204 -180 -214 -300
Total Depreciation and Amortization (D&A)		 0.13 1.70 6.39 7.62 3.83 13
Debt-free, Cash-free Net Working Capital to Revenue		 -1.01% -1.58% -5.06% -2.08% -4.24% -8.52%
Debt-free Net Working Capital to Revenue		 0.82% 65.78% 85.89% 32.01% 21.10% 11.82%
Net Working Capital to Revenue		 0.82% 65.78% 70.14% 32.01% 20.25% 11.82%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.96) ($0.58) ($0.32) ($0.11) $0.58
Adjusted Weighted Average Basic Shares Outstanding		 0.00 191.35M 186.78M 204.52M 209.34M 215.94M
Adjusted Diluted Earnings per Share		 $0.00 ($0.96) ($0.58) ($0.32) ($0.11) $0.53
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 191.35M 186.78M 204.52M 209.34M 236.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 25.16M 205.07M 208.46M 214.25M 222.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -11 -81 -48 -21 43
Normalized NOPAT Margin		 -63.09% -7.13% -29.62% -9.13% -2.36% 2.93%
Pre Tax Income Margin		 -87.18% -12.09% -40.75% -12.47% -2.47% 4.86%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -194.05 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -141.16 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -198.89 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -146.01 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -18.53% -32.40% 0.00% -8.49% 65.88%

Quarterly Metrics and Ratios for Hims & Hers Health

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 95.27% 97.41% 88.30% 83.08% 56.52% 47.50% 45.81% 51.82% 77.13% 95.09%
EBITDA Growth		 -2.65% 66.22% 36.00% 65.08% 63.94% 132.48% 266.50% 353.04% 541.80% 756.87%
EBIT Growth		 1.35% 64.71% 40.09% 63.54% 63.32% 119.91% 228.12% 287.22% 441.14% 915.07%
NOPAT Growth		 27.76% 46.19% 33.43% 54.25% 57.19% 97.21% 212.70% 268.99% 1,297.14% 9,673.78%
Net Income Growth		 -18.19% 65.00% 38.06% 63.63% 59.84% 111.41% 210.54% 285.79% 1,098.92% 1,990.36%
EPS Growth		 -12.50% 54.55% 37.50% 70.00% 55.56% 120.00% 200.00% 300.00% 900.00% 900.00%
Operating Cash Flow Growth		 137.50% -116.39% 148.87% 363.15% 320.90% 427.18% 172.47% 218.52% 238.48% 292.96%
Free Cash Flow Firm Growth		 -127.70% 92.93% 100.78% 99.36% 75.06% 114.21% -891.54% 812.83% 354.72% -1,799.80%
Invested Capital Growth		 -0.32% 1.49% -6.74% -3.90% -2.07% -1.25% 15.54% 2.25% 51.29% 35.26%
Revenue Q/Q Growth		 27.54% 15.44% 14.09% 8.99% 9.04% 8.79% 12.79% 13.47% 27.22% 19.82%
EBITDA Q/Q Growth		 6.25% 41.43% 13.33% 27.15% 3.17% 152.75% 347.44% 10.72% 69.05% 2.31%
EBIT Q/Q Growth		 4.12% 41.51% 12.77% 25.94% 3.54% 131.75% 464.80% 8.23% 75.75% -5.52%
NOPAT Q/Q Growth		 1.03% 41.93% 2.95% 18.00% 7.38% 96.21% 4,017.96% 22.97% 556.09% -69.71%
Net Income Q/Q Growth		 4.26% 42.11% 7.70% 28.91% -5.73% 116.45% 793.82% 19.49% 468.46% -65.57%
EPS Q/Q Growth		 10.00% 44.44% 0.00% 40.00% -33.33% 125.00% 400.00% 20.00% 433.33% -68.75%
Operating Cash Flow Q/Q Growth		 193.60% -212.26% 241.14% 77.43% 49.71% -12.73% 17.54% 107.42% 59.10% 1.31%
Free Cash Flow Firm Q/Q Growth		 92.26% 25.93% 113.89% -179.85% -203.51% 142.19% -874.20% 171.91% 8.46% -381.52%
Invested Capital Q/Q Growth		 -8.41% 5.25% -2.85% 2.61% -6.66% 6.13% 13.68% -9.19% 38.10% -5.12%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 79.02% 79.15% 80.42% 81.84% 82.62% 82.74% 82.36% 81.30% 79.16% 76.81%
EBITDA Margin		 -11.62% -5.90% -4.51% -3.02% -2.68% 1.30% 5.15% 5.03% 6.68% 5.70%
Operating Margin		 -13.80% -6.94% -5.90% -4.44% -3.77% -0.16% 3.56% 3.49% 5.57% 3.87%
EBIT Margin		 -13.02% -6.60% -5.07% -3.45% -3.05% 0.89% 4.46% 4.25% 5.88% 4.63%
Profit (Net Income) Margin		 -13.01% -6.52% -5.28% -3.44% -3.34% 0.50% 4.00% 4.21% 18.82% 5.41%
Tax Burden Percent		 99.92% 98.90% 103.99% 99.82% 109.41% 56.69% 89.72% 99.05% 320.38% 116.75%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 43.31% 10.28% 0.95% -220.38% -16.75%
Return on Invested Capital (ROIC)		 -34.14% -19.52% -19.15% -16.45% -16.85% -0.61% 22.15% 27.73% 143.55% 43.42%
ROIC Less NNEP Spread (ROIC-NNEP)		 -31.80% -18.07% -17.99% -16.07% -16.04% -1.36% 20.97% 26.59% 141.85% 41.74%
Return on Net Nonoperating Assets (RNNOA)		 19.79% 10.74% 10.52% 9.31% 9.81% 0.82% -12.15% -16.21% -84.84% -26.13%
Return on Equity (ROE)		 -14.34% -8.78% -8.64% -7.13% -7.04% 0.20% 10.01% 11.53% 58.71% 17.29%
Cash Return on Invested Capital (CROIC)		 -43.47% -38.14% -26.20% -23.15% -20.82% -14.44% 13.03% 5.48% 13.67% 40.92%
Operating Return on Assets (OROA)		 -14.41% -8.83% -8.25% -6.37% -6.07% 1.92% 10.38% 10.43% 14.36% 11.91%
Return on Assets (ROA)		 -14.40% -8.74% -8.58% -6.36% -6.64% 1.09% 9.31% 10.33% 46.02% 13.91%
Return on Common Equity (ROCE)		 -14.34% -8.78% -8.64% -7.13% -7.04% 0.20% 10.01% 11.53% 58.71% 17.29%
Return on Equity Simple (ROE_SIMPLE)		 -27.64% 0.00% -19.02% -14.68% -10.86% 0.00% -0.68% 5.00% 23.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -8.12 -7.88 -6.47 -5.99 -0.23 8.88 11 72 22
NOPAT Margin		 -9.66% -4.86% -4.13% -3.11% -2.64% -0.09% 3.19% 3.46% 17.85% 4.51%
Net Nonoperating Expense Percent (NNEP)		 -2.34% -1.45% -1.17% -0.37% -0.81% 0.75% 1.18% 1.14% 1.70% 1.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.61% - - - -0.06% - - - 4.55%
Cost of Revenue to Revenue		 20.98% 20.85% 19.58% 18.16% 17.38% 17.26% 17.64% 18.70% 20.84% 23.19%
SG&A Expenses to Revenue		 18.12% 16.49% 15.99% 14.98% 15.84% 13.10% 12.43% 12.85% 11.11% 9.98%
R&D to Revenue		 5.51% 4.97% 5.63% 5.68% 5.41% 5.44% 5.51% 5.91% 5.25% 4.94%
Operating Expenses to Revenue		 92.82% 86.09% 86.33% 86.28% 86.40% 82.90% 78.80% 77.80% 73.59% 72.94%
Earnings before Interest and Taxes (EBIT)		 -19 -11 -9.68 -7.17 -6.92 2.20 12 13 24 22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -9.86 -8.61 -6.27 -6.07 3.20 14 16 27 27
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.72 4.27 6.61 6.15 4.04 5.48 9.52 11.98 9.09 11.08
Price to Tangible Book Value (P/TBV)		 6.49 7.44 11.43 10.40 6.69 8.79 15.20 18.54 14.15 16.48
Price to Revenue (P/Rev)		 2.60 2.53 3.36 2.77 1.67 2.16 3.42 4.06 3.22 3.58
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 240.13 39.51 41.91
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.42% 2.53% 2.39%
Enterprise Value to Invested Capital (EV/IC)		 7.73 8.72 14.67 13.51 9.12 12.83 20.79 30.51 20.13 28.24
Enterprise Value to Revenue (EV/Rev)		 2.18 2.19 3.06 2.50 1.42 1.92 3.21 3.85 3.01 3.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 594.10 150.40 62.19 59.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 6,010.45 194.69 72.55 69.48
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 81.19 399.96 44.49 45.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 799.80 69.57 25.05 22.77 34.32 32.46 20.06 19.84
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 171.03 562.52 177.30 79.35
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.04 0.00 0.00 0.01 0.02 0.02 0.02 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.62 -0.59 -0.58 -0.58 -0.61 -0.60 -0.58 -0.61 -0.60 -0.63
Leverage Ratio		 1.21 1.22 1.18 1.20 1.25 1.23 1.25 1.28 1.32 1.40
Compound Leverage Factor		 1.21 1.22 1.18 1.20 1.25 1.23 1.25 1.28 1.32 1.40
Debt to Total Capital		 4.00% 0.00% 0.00% 1.47% 2.05% 2.11% 2.11% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 4.00% 0.00% 0.00% 1.47% 2.05% 2.11% 2.11% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.00% 100.00% 100.00% 98.53% 97.95% 97.89% 97.89% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.17 0.00 0.00 -0.11 -0.22 -0.42 1.43 0.00 0.00 0.00
Net Debt to EBITDA		 2.40 0.00 0.00 4.52 6.66 12.04 -37.80 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.24 0.00 0.00 -0.13 -0.24 -0.36 0.20 0.00 0.00 0.00
Net Debt to NOPAT		 3.37 0.00 0.00 5.17 7.23 10.36 -5.17 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.95 15.21 20.29 17.89 10.43 12.96 20.56 23.72 16.70 15.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.49 4.52 4.01 3.53 3.03 3.00 2.80 2.68 2.14 1.79
Quick Ratio		 2.97 3.75 3.28 2.90 2.57 2.50 2.18 2.09 1.66 1.36
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -10 1.40 -1.12 -3.39 1.43 -11 7.96 8.63 -24
Operating Cash Flow to CapEx		 305.20% -257.14% 377.81% 245.13% 425.52% 196.31% 185.11% 889.38% 1,449.87% 321.31%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 1.11 1.34 1.63 1.85 1.99 2.16 2.33 2.45 2.44 2.57
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 6.38 6.73 7.86 6.83 6.74 7.13 6.68 6.13 6.59 6.98
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 4.32 4.55 4.19 4.29 3.98 4.16 4.14 3.99 3.99 4.52
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 57.21 54.23 46.47 53.43 54.18 51.16 54.63 59.54 55.37 52.27
Days Payable Outstanding (DPO)		 84.53 80.30 87.04 84.99 91.61 87.66 88.15 91.57 91.46 80.76
Cash Conversion Cycle (CCC)		 -27.33 -26.07 -40.57 -31.56 -37.43 -36.50 -33.53 -32.03 -36.09 -28.49
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 126 132 128 132 123 130 148 135 186 176
Invested Capital Turnover		 3.53 4.02 4.63 5.29 6.38 6.64 6.94 8.01 8.04 9.62
Increase / (Decrease) in Invested Capital		 -0.41 1.94 -9.28 -5.35 -2.60 -1.66 20 2.97 63 46
Enterprise Value (EV)		 970 1,152 1,884 1,779 1,122 1,673 3,083 4,109 3,745 4,983
Market Capitalization		 1,156 1,332 2,068 1,968 1,327 1,887 3,280 4,337 3,999 5,283
Book Value per Share		 $1.50 $1.50 $1.50 $1.53 $1.56 $1.62 $1.61 $1.69 $2.03 $2.18
Tangible Book Value per Share		 $0.86 $0.86 $0.87 $0.90 $0.94 $1.01 $1.01 $1.09 $1.30 $1.47
Total Capital		 324 312 313 325 335 351 352 362 440 477
Total Debt		 13 0.00 0.00 4.78 6.86 7.41 7.41 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -185 -180 -184 -188 -206 -214 -196 -227 -254 -300
Capital Expenditures (CapEx)		 1.96 2.61 2.51 6.86 5.92 11 14 6.03 5.88 27
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -11 -15 -20 -38 -37 -28 -45 -80 -126
Debt-free Net Working Capital (DFNWC)		 180 169 169 173 175 184 176 182 174 174
Net Working Capital (NWC)		 167 169 169 168 168 177 168 182 174 174
Net Nonoperating Expense (NNE)		 4.85 2.78 2.18 0.69 1.58 -1.47 -2.24 -2.37 -3.91 -4.31
Net Nonoperating Obligations (NNO)		 -185 -180 -184 -188 -206 -214 -196 -227 -254 -300
Total Depreciation and Amortization (D&A)		 2.03 1.17 1.08 0.90 0.85 1.01 1.92 2.44 3.22 5.15
Debt-free, Cash-free Net Working Capital to Revenue		 -4.23% -2.08% -2.46% -2.85% -4.79% -4.24% -2.89% -4.22% -6.47% -8.52%
Debt-free Net Working Capital to Revenue		 40.42% 32.01% 27.46% 24.32% 22.02% 21.10% 18.33% 17.08% 13.99% 11.82%
Net Working Capital to Revenue		 37.50% 32.01% 27.46% 23.65% 21.16% 20.25% 17.55% 17.08% 13.99% 11.82%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.05) ($0.05) ($0.03) ($0.04) $0.01 $0.05 $0.06 $0.35 $0.12
Adjusted Weighted Average Basic Shares Outstanding		 205.23M 204.52M 207.14M 208.42M 210.13M 209.34M 213.45M 214.62M 216.62M 215.94M
Adjusted Diluted Earnings per Share		 ($0.09) ($0.05) ($0.05) ($0.03) ($0.04) $0.01 $0.05 $0.06 $0.32 $0.10
Adjusted Weighted Average Diluted Shares Outstanding		 205.23M 204.52M 207.14M 208.42M 210.13M 209.34M 229.36M 234.79M 235.07M 236.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 207.74M 208.46M 209.32M 211.02M 211.99M 214.25M 214.79M 217.08M 218.48M 222.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -8.12 -7.88 -6.47 -5.99 -0.23 8.88 11 16 13
Normalized NOPAT Margin		 -9.66% -4.86% -4.13% -3.11% -2.64% -0.09% 3.19% 3.46% 3.90% 2.71%
Pre Tax Income Margin		 -13.02% -6.60% -5.07% -3.45% -3.05% 0.89% 4.46% 4.25% 5.88% 4.63%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -8.49% -1,278.73% 276.17% 79.04% 65.88%

Frequently Asked Questions About Hims & Hers Health's Financials

When does Hims & Hers Health's fiscal year end?

According to the most recent income statement we have on file, Hims & Hers Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Hims & Hers Health's net income changed over the last 5 years?

Hims & Hers Health's net income appears to be on a downward trend, with a most recent value of $126.04 million in 2024, falling from -$72.06 million in 2019. The previous period was -$23.55 million in 2023.

What is Hims & Hers Health's operating income?
Hims & Hers Health's total operating income in 2024 was $61.90 million, based on the following breakdown:
  • Total Gross Profit: $1.17 billion
  • Total Operating Expenses: $1.11 billion
How has Hims & Hers Health revenue changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's total revenue changed from $82.56 million in 2019 to $1.48 billion in 2024, a change of 1,688.5%.

How much debt does Hims & Hers Health have?

Hims & Hers Health's total liabilities were at $230.82 million at the end of 2024, a 137.6% increase from 2023, and a 2,724.2% increase since 2019.

How much cash does Hims & Hers Health have?

In the past 5 years, Hims & Hers Health's cash and equivalents has ranged from $1.51 million in 2019 to $220.58 million in 2024, and is currently $220.58 million as of their latest financial filing in 2024.

How has Hims & Hers Health's book value per share changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's book value per share changed from 0.20 in 2019 to 2.18 in 2024, a change of 997.6%.


Related Companies

This page (NYSE:HIMS) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...
Altimetry | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
China’s next move could destroy U.S. tech
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...
Investors Alley | Sponsored
This isn’t a trade war. It’s worse…
Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...
Stansberry Research | Sponsored
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...
Crypto 101 Media | Sponsored